Abstract
Hundreds of thousands of genetic variants have been reported to cause severe monogenic diseases, but the probability that a variant carrier will develop the disease (termed penetrance) is unknown for virtually all of them. Additionally, the clinical utility of common polygenetic variation remains uncertain. Using exome sequencing from 77,184 adult individuals (38,618 multi-ancestral individuals from a type 2 diabetes case-control study and 38,566 participants from the UK Biobank, for whom genotype array data were also available), we applied clinical standard-of-care gene variant curation for eight monogenic metabolic conditions. Rare variants causing monogenic diabetes and dyslipidemias displayed effect sizes significantly larger than the top 1% of the corresponding polygenic scores. Nevertheless, penetrance estimates for monogenic variant carriers averaged below 60% in both studies for all conditions except monogenic diabetes. We assessed additional epidemiologic and genetic factors contributing to risk prediction, demonstrating that inclusion of common polygenic variation significantly improved biomarker estimation for two monogenic dyslipidemias.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH/NIDDK U01 DK105554 to JCF. This research has been conducted using the UK Biobank Resource under application number 27892. MSU is supported by NIH/NIDDK K23 DK114551. AODL was supported by NIH/NICHD K12 HD052896. MB is supported by NIH/NIDDK DK062370. JCF is also supported by NIH/NIDDK K24 DK110550. Funding for GO ESP was provided by NHLBI grants RC2 HL 103010 (HeartGO), with exome sequencing was performed through NHLBI grants RC2 HL 102925 (BroadGO) and RC2 HL 102926 (SeattleGO). HeartGO components and their support include Atherosclerosis Risk in Communities (NHLBI contracts N01 HC 55015, N01 HC 55016, N01HC 55017, N01 HC 55018, N01 HC 55019, N01 HC 55020, and N01 HC 55021); Cardiovascular Health Study (NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086); and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, and R01HL120393, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided through R01AG023629 from the National Institute on Aging. A full list of principal Cardiovascular Health Study investigators and institutions can be found at CHS-NHLBI.org; Coronary Artery Risk Development in Young Adults (NHLBI contracts N01 HC95095, N01 HC48047, N01 HC48048, N01 HC48049, and N01 HC48050); Framingham Heart Study (NHLBI contract N01 HC-25195 and grants NS17950, AG08122, and AG033193); Jackson Heart Study (NHLBI contracts N01 HC 95170, N01 HC 95171, and N01 HC 95172); Multi-Ethnic Study of Atherosclerosis (NHLBI contracts N01 HC 95159 through N01 HC 95169 and grant 024156). Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. We gratefully acknowledge the Eunice Kennedy National Institute of Child Health and Human Development for support of the MODY variant curation through U24 HD093486 (to TIP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities (NIMHD). The authors also wish to thank the staffs and participants of the JHS. Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center, based at the University of Copenhagen, Denmark and partially funded by an unconditional donation from the Novo Nordisk Foundation (www.cbmr.ku.dk) (Grant number NNF18CC0034900). The LOLIPOP study is supported by the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre Imperial College Healthcare NHS Trust, the NIHR Official Development Assistance (ODA, award 16/136/68), the European Union FP7 (EpiMigrant, 279143) and H2020 programs (iHealth-T2D, 643774). The views expressed are those of the author(s) and not necessarily those of the Imperial College Healthcare NHS Trust, the NHS, the NIHR or the Department of Health. We thank the participants and research staff who made the study possible. JC is supported by the Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator (STaR) Award (NMRC/STaR/0028/2017). The TwinsUK study was funded by the Wellcome Trust and European Community s Seventh Framework Programme (FP7/2007-2013). The TwinsUK study also receives support from the National Institute for Health Research (NIHR) funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust in partnership with King's College London. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. MMcC has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, MMcC is an employee of Genentech, and a holder of Roche stock. MMcC wishes to acknowledge NIDDK U01 DK105535 and Wellcome: 090532, 098381, 106130, 203141, 212259. The San Antonio Mexican American Family Studies (SAMAFS) are supported by the following grants/institutes. The San Antonio Family Heart Study (SAFHS) and San Antonio Family Diabetes/Gallbladder Study (SAFDGS) were supported by U01DK085524, R01 HL0113323, P01 HL045222, R01 DK047482 and R01 DK053889. The Veterans Administration Genetic Epidemiology Study (VAGES) study was supported by a Veterans Administration Epidemiologic grant. The Family Investigation of Nephropathy and Diabetes - San Antonio (FIND-SA) study was supported by NIH grant U01DK57295. The SAMAFS research team acknowledges the contributions of late Dr. H. E. Abboud to the research activities of the SAMAFS. The KARE cohort was supported by grants from Korea Centers for Disease Control and Prevention(4845-301, 4851-302, 4851-307) and intramural grants from the Korea National Institute of Health (2016-NI73001-00, 2019-NG-053-01). RJFL is supported by the NIH (R01DK110113, R01DK107786, 1R01DK124097). NC is supported by a grant from the Canadian Institutes of Health Research (CIHR Fellowship). The Mount Sinai BioMe Biobank has been supported by The Andrea and Charles Bronfman Philanthropies and in part by Federal funds from the NHLBI and NHGRI (U01HG00638001; U01HG007417; X01HL134588). The Framingham Heart Study (FHS) acknowledges the support of Contracts NO1-HC-25195, HHSN268201500001, and 75N92019D00031 from the National Heart, Lung and Blood Institute and grant supplement R01 HL092577-06S1 for this research. We also acknowledge the dedication of the FHS study participants without whom this research would not be possible. Dr. Vasan is supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples were approved for use by their home institution's institutional review board or ethics committee. Analysis of the data was approved by the Mass General Brigham (formerly Partners) institutional review board in Boston Massachusetts.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequence data and phenotypes for this study are either currently available or will be made available via the database of Genotypes and Phenotypes (dbGAP) and/or the European Genome-phenome Archive, as indicated in Supplementary Table 2.
